Pharmacodynamic modelling of resistance to epidermal growth factor receptor inhibition in brain metastasis mouse models

ConclusionsThe developed model to describe resistance suggests that the resistance to EGFR-inhibition seen in these xenografts is best described by assuming a small percentage of cells are resistant to treatment at baseline. This model suggests changes to dosing and dosing schedule may not prevent resistance to treatment developing, and that additional treatments would need to be used in combination to overcome resistance.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research